一个真实世界的药监测研究FDA不良事件报告系统 (FAERS) 事件对于etrasimod
Yingxiu Wu1,2, Wei Ke1,2, Huibiao Li3
1Foshan Hospital of Traditional Chinese Medicine, Foshan, Guangdong, China.
Frontiers in pharmacology
|November 27, 2025
概括
埃特拉西莫德的安全性概况总体上是一致的,有一些特定的胃肠道和神经系统事件. 相对分析表明,与其他基-1-酸盐 (S1P) 受体调节器相比,它可能具有独特的安全性.
科学领域:
- 药物监督 药物监督 药物监督
- 免疫学 免疫学 免疫学
- 胃肠病学 胃肠病学
背景情况:
- 氨酸-1-酸盐 (S1P) 受体调节器用于自身免疫性疾病.
- 了解像埃特拉西莫德这样的新药的营销后安全性至关重要.
- 需要与已建立的S1P调制器进行比较的安全数据.
研究的目的:
- 通过使用FDA不良事件报告系统 (FAERS) 数据来描述etrasimod的营销后安全性.
- 为了比较埃特拉西莫德与其他S1P受体调节剂 (fingolimod,ozanimod) 的安全性.
主要方法:
- 从FAERS (2004年第一季度 - 2025年第二季度) 获取了etrasimod AE报告.
- 使用ROR,PRR,BCPNN和MGPS进行了不成比例的分析.
- 对fingolimod和ozanimod进行了比较分析.
主要成果:
- 鉴定了967名患者的2104份AE报告.
- 最常见的副作用:药物无效,情况恶化,头痛,头.
- 强烈的信号:性直肠炎,便calprotectin的增加,斑点.
- 与其他S1P调节剂相比,Etrasimod对淋巴细胞数量的减少显示出潜在的更有利的信号.
结论:
- 更新的分析证实了埃特拉西莫德与类相关的副作用的确立安全概况.
- 没有发现任何意外的安全信号.
- 经常报告缺乏疗效,需要密切监测.
- 比较数据有助于临床医生选择S1P受体调节器疗法.
相关概念视频
Pharmacovigilance
1.6K
Post-marketing surveillance is a critical component of pharmaceutical regulation, often uncovering unanticipated adverse drug reactions (ADRs) once a drug is widely used over an extended period.
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
1.6K
Drug Regulation
2.7K
Drug regulation encompasses the management of drug usage by evaluating its safety and efficacy through assessments conducted by regulatory authorities. Regrettably, the history of drug regulation is marred by several catastrophic events. One such incident is the Elixir Sulfanilamide tragedy, in which the toxic compound diethyl glycol was included in a sweet-tasting medication, leading to numerous fatalities. This event prompted the enactment of the Food, Drug, and Cosmetic Act in 1938. Under...
2.7K
Antiepileptic Drugs: Potassium Channel Activators
611
Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
Ezogabine has gained approval as an adjunctive treatment...
611
Therapeutic Drug Monitoring: Affecting Factors
182
Therapeutic Drug Monitoring (TDM) is the clinical practice of measuring specific drug levels in a patient's blood or body tissues to manage and optimize therapy. TDM is crucial for drugs with narrow therapeutic windows, like warfarin and phenytoin, where incorrect doses can lead to treatment failure or severe side effects. This monitoring ensures the dosage administered is within a safe and effective range. The factors affecting therapeutic drug monitoring include:Patient-Specific Factors:a.
182
Therapeutic Drug Monitoring: Overview and Classification
275
Therapeutic Drug Monitoring (TDM) is a clinical practice that measures specific drug levels in a patient's blood at designated intervals to ensure the drug concentration stays within a therapeutic range. This monitoring is crucial for optimizing individual dosage regimens, enhancing therapeutic efficacy, and minimizing drug-related toxicity. TDM is vital for drugs with narrow therapeutic windows, significant variability in pharmacokinetics, and a clear correlation between plasma levels and...
275
Clinical Trials: Overview
4.5K
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
4.5K


